Untitled - D Ank Unlimited

eticuloendothelial blockade 620 retroviral oncogene
Bone marrow
Stem cell
Macrophage
reticuloendothelial blockade
The temporary paralysis of the phagocytic ability of cells of
the mononuclear phagocytic system through the injection of
excess amounts of inert particles such as colloidal carbon,
gold, or iron. After the mononuclear phagocytes have
expended their entire phagocytic capabilities by taking up
these inert particles, they can no longer phagocytize administered
microorganisms or other substances that would
normally be phagocytized.
reticuloendothelial system (RES)
A former term for the mononuclear phagocyte system
that includes Kupffer’s cells lining the sinusoids of the
liver and macrophages of the spleen and lymph nodes.
Aschoff introduced the term to describe cells that could
take up and retain vital dyes and particles injected into
the body. In addition to macrophages, less active phagocytic
cells such as fibroblasts and endothelial cells were
included in the original definition. The principal function
of the mononuclear phagocyte system is removal of
unwelcome particles from the blood. RES activity may
be measured by the elimination rate of radiolabeled molecules
or cells such as albumin or erythrocytes coated
with antibody.
reticulosis
Refer to lymphoma.
reticulum cell
Refer to reticular cell.
Blood Tissue
Monocyte
Microglia
Osteoclast
Macrophage
(spleen,
lung, etc.)
Endothelial
cells
Reticuloendothelial system (RES).
Dendritic cell
Langerhans cell
Mesangium
Tissue
mesenchyme
Reticular
cell
reticulum cell sarcoma
Obsolete term for large cell lymphoma.
retina autoantibodies
Autoantibodies found in ANA-negative patients with
cancer-associated retinopathy (CAR) syndrome. These
antibodies are specific for five antigens: retinal S, associated
with ocular inflammation or uveitis; rhodopsin; interphotoreceptor
in retinol-binding protein (IRBP); phosducin;
and CAR autoantigen (recoverin), a 23-kDa protein closely
associated with CAR syndrome. Retina antibodies are
assayed using enzyme immunoassay (EIA), immunoblotting,
and dot blotting; there is no known clinical correlation
for retina autoantibodies.
Retrovir ®
A synthetic nucleoside analog of thymidine in which the
3′ hydroxy group is replaced by an azido group. The FDA
approved it for the treatment of human immunodeficiency
virus (HIV). The mechanism of action includes the conversion
of zidovudine to its active metabolite zidovudine
5′ triphosphate, which inhibits the activity of the HIV
reverse transcriptase by competing for utilization with the
natural substrate and by its incorporation into viral DNA.
Zidovudine is the active component.
retroviral oncogene
The incorporation of a proto-oncogene copy by an integrated
retrovirus into its genome may lead to conversion by
adjacent regulatory sequences of the proto-oncogene into a